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PENGENALPASTIAN PENANDA-PENANDA BIO DALAM KARSINOMA 
DUKTAL MENYUSUP: SATU PENDEKATAN PROTEOMIK 
 
ABSTRAK 
 
Kanser ialah suatu penyakit disifatkan dengan pertumbuhan sel-sel yang 
tidak terancang. Payudara wanita mengandungi kelenjar mamari yang dikhaskan 
untuk merembes susu semasa wanita mengandung. Kanser payudara wanita 
merupakan salah satu punca utama kematian wanita di seluruh dunia. Di Malaysia, 
kanser payudara merupakan kanser yang paling lazim didiagnosiskan. Dalam hal ini, 
kaum Cina merangkumi kes kanser payudara yang paling banyak, diikuti dengan 
kaum India dan kaum Melayu. Jenis kanser payudara yang paling lazim ialah 
karsinoma duktal menyusup (IDC). Dalam kajian ini, satu pendekatan proteomik 
dilakukan untuk menganalisisa protein-protein dari tisu-tisu payudara manusia. 
Teknik pengektrakan protein secara bersambung digunakan untuk mengekstrak 
protein daripada tisu-tisu dan seterusnya protein-protein ini dipisahkan dengan 
elektroforesis gel poliakrilamida dua-dimensi (2D-PAGE). Dalam kaedah ini, 
protein-protein dipisahkan mengikut takat isoelektrik (pI) dan jisim molekul masing-
masing. Gel-gel diwarnakan dengan pewarna biru Coomassie dan imej-imej gel 
diambil dan analisa imej-imej dijalankan dengan menggunakan sistem pengimej. 
Keamatan tompok-tompok protein sasaran dianalisa dengan menggunakan analisis 
komponen-komponen utama (PCA) dan analisis pembezalayan linear (LDA) untuk 
menghitung kesahihan protein-protein ini sebagai penunjuk dalam IDC. Tompok-
tompok protein sasaran dipotong daripada gel dan diproses dengan menggunakan 
teknik penghadaman dalam-gel dengan enzim tripsin. Peptida-peptida hasil hadaman 
xviii 
 
tripsin dianalisisa dengan LC-MS/MS. Spektrum ion produk yang dihasilkan dalam 
imbasan MS/MS dicarikan pada pangkalan carian data protein MASCOT enjin 
carian. Dua puluh empat protein yang larut air dan sepuluh protein hidrofobik 
didapati diekspres dalam kadar yang berbeza antara tisu-tisu payudara normal dan 
kanser. Antara peranan protein yang dikenalpastikan adalah dalam pertumbuhan dan 
penyelenggaran sel, komunikasi sel, transduksi isyarat, metabolisma dan 
pengangkutan. Oleh sebab protein ialah komponen berfungsi yang mengawalatur 
aktiviti sel, pengenalpastian protein-protein ini memberi pemahaman yang lebih 
mendalam tentang perkembangan kanser payudara pada pesakit-pesakit Malaysia. 
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IDENTIFICATION OF BIOMARKERS IN INFILTRATING DUCTAL 
CARCINOMA: A PROTEOMICS APPROACH 
 
ABSTRACT 
 
Cancer is a disease characterized by disordered cell growth. The female 
breast houses the mammary glands which are specialized to secrete milk following 
pregnancy. Female breast cancer is one of the leading causes of female mortality 
worldwide. In Malaysia, breast cancer is the most commonly diagnosed cancer in 
women. Of these, the Chinese had the most number of breast cancer cases, followed 
by the Indians and the Malays. The most common type of breast cancer is 
infiltrating ductal carcinoma (IDC). In this study, a proteomics approach was used in 
the analysis of proteins from human breast tissues. Sequential protein extraction 
technique was used to extract the proteins from the tissues and the proteins were 
separated by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). 
Using this method, the proteins were separated according to their isoelectric point 
(pI) and molecular mass. The gels then were stained using Coomassie Blue and their 
images were captured and analyzed by an imaging system. The target proteins spots’ 
intensities were analyzed using principal components analysis (PCA) and linear 
discriminant analysis (LDA) for their significance in indicating IDC. The targeted 
protein spots were excised from the gel and were subjected to in-gel digestion using 
the enzyme trypsin. The tryptic peptides were analyzed by LC/MS/MS. The 
generated product ion spectrum in the MS/MS scan was searched against the 
MASCOT protein database search engine. Twenty-four aqueous soluble proteins 
and ten hydrophobic proteins were found to be differentially expressed in normal 
xx 
 
and cancer breast tissues. Among the roles the identified proteins were in cell 
growth and maintenance, cell communication, signal transduction, metabolism and 
transport.   As proteins are the functional components that regulate cellular activity, 
identification of these proteins provides a better understanding to the development 
of breast cancer amongst Malaysian patients. 
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CHAPTER 1 
INTRODUCTION 
 
1.1  Cancer 
1.1.1 Definition 
Cancer refers to diseases characterized by a common type of disordered cell 
growth (Creasey, 1981; King and Robins, 2006). This normally leads to invasion and 
destruction of the surrounding tissues or spread to other parts of the body (King and 
Robins, 2006). The disease is usually visible as a mass of cells called tumour as a 
result of a series of biological and chemical changes which may take years to 
develop (Franks, 1986). Cancer may affect people regardless of age and sex. Out of 
61 million cases of death reported worldwide in 2007, 7.9 million or 13% is caused 
by cancer, making it one of the world’s leading causes of death (World Health 
Organization, 2008).  
Tumours, strictly defined as neoplasms, are classified as benign, in situ and 
malignant. Tumours are more commonly exhibited in epithelial cells (King and 
Robins, 2006). Benign tumours are non-cancerous and are usually harmless. They 
are composed of well-differentiated cells (Vincent, 1985) and do not infiltrate 
adjacent tissues and remain non-invasive (Creasey, 1981). In situ tumours usually 
develop in the epithelium and are usually small. They have the morphological 
appearances of cancer cells but remain in the epithelial layer. They do not invade the 
basement membrane and the supporting mesenchyme. However, malignant tumours 
are life threatening as they are capable of invading and destroying nearby tissues. 
They also display cellular abnormalities (Franks, 1986). A group of cells in a 
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malignant tumour may also break away and spread to other parts of the body, a 
process called metastasis (Hart, 1986; Ruddon, 1995; King and Robins, 2006). 
Many different factors are involved in the potential development of cancer. 
They include: age, race, family history, personal history of cancer, presence of 
viruses, mutations in cell regulation genes and tumour suppressing genes, exposure 
to carcinogens, lack of physical activity and diet (Franks, 1986; National Cancer 
Institute, 2007a).
Cancers are classified according to the type of cell it originates from and its 
location. The most common form of malignancy is those derived from epithelial 
cells and is called carcinoma. The other major type of cancer involves the 
mesenchyme or connective tissue cells are called sarcoma (Creasey, 1981, Jass, 
1999). As of now, there is no known cure for cancer. Cancer treatments available 
include surgery, radiotherapy, chemotherapy, hormonal therapy and immunotherapy 
(Creasey, 1981; Franks, 1986; King and Robins, 2006). 
 
1.1.2 Carcinogenesis 
Carcinogenesis is a multistage process of cancer development from a 
normal single cell. Carcinogenesis can be divided into three main stages: initiation, 
promotion and progression (King and Robins, 2006). In the initiation stage, normal 
cells are exposed to cancer causing agents or carcinogens for a period of time. This 
stage occurs rapidly and may persist for a long time. The primary consequence of 
carcinogen exposure is likely to be the damage to the cells’ genetic material. 
Initiated cells usually remain latent until acted upon by promoting agents (Franks, 
1986).  
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As there are a series of changes after the initiation stage, tumour formation 
may not happen immediately. Tumour promotion may be induced by the carcinogen 
or by other promoting agents which by themselves do not cause tumour formation. 
Here, the slow growing ‘transformed’ cells are induced by the promoting agents to 
divide and grow rapidly. Many agents can cause cell division, but only promoters 
are able to initiate tumour development by interfering with the cell’s differentiation 
process. Even as this happens, the cells may still be acted upon by normal growth 
inhibiting factors in the body so that the final outcome depends on the balance 
between the factors and the extent of changes within the cell (Franks, 1986). 
In the progression stage, the tumours will undergo further changes such as 
dedifferentiation, increased autonomous growth and aggressive behaviour. This 
stage reflects the multiple changes in growth regulatory mechanisms and ultimately 
results in autonomous cell growth, which is the ability to grow outside their normal 
environment and spread to other parts of the body (King and Robins, 2006). 
 
Figure 1.1 Factors influencing tumour development showing progression 
from normal to invasive tumour (Franks, 1986). 
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   Normal growth control is regulated by two different genes: oncogenes, 
which function to accelerate cell division, and tumour suppressing genes, which 
does the opposite. Under normal conditions, the relationship between these two 
processes is delicately balanced such that cells undergo controlled patterns of growth 
and division. Cancer development is associated with an accumulation of mutations 
of these genes. The carcinogen is believed to have caused the damage or mutation of 
these genes which disturb this balance in favour of cell growth and proliferation 
(Sutherland, 1999). Besides these genes, cancers may form as a result of mutation to 
proto-oncogenes, cell cycle regulator genes, housekeeping genes, metastasis genes 
and drug resistance and susceptibility genes (Trent, 1999). In addition, defects in 
gene repair mechanisms may induce genome-wide instability, which may lead to 
further progression of cancer (Baak et al., 2003). 
 
 
 
Figure 1.2 Growth of cancer. Cancer cells (shaded) grow and multiply to form 
tumours inside the tissue. (Susan G. Komen For The Cure, 2007). 
 
1.1.3 Metastasis 
Metastasis is a process when cancer cells escape from the primary organ or 
tissue where the tumour initially occurs and spread to other parts of the body (King 
and Robins, 2006). At the new location, cancer cells may again begin to divide 
abnormally to form a secondary site. Metastasis usually forms part of the natural 
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history of malignant tumours and is the major cause of death in cancer. The ability 
of malignant cells to break away and invade surrounding tissues represents the main 
difference between benign and malignant tumours (Gallagher, 1985; King and 
Robins, 2006). 
Metastasis occurs in several steps. Following tumour development and 
growth, the cancer cells will invade and infiltrate the surrounding tissue, traverse the 
basal membrane and migrate through the intracellular space to reach the blood or 
lymphatic vessels. They penetrate the vessel walls (intravasation) in order to release 
the tumour cells into the circulation. Once in circulation, they have to avoid 
destruction while being transported to a new location. When the cells have arrived at 
a remote site, they arrest in the capillary beds of the remote site and then breach the 
blood or lymphatic vessel walls again (extravasation). Having reached the metastatic 
site, the tumour cells will proliferate in the new environment. If these steps are 
completed, the result will be a formation of a secondary tumour in a distant part of 
the body (Hart, 1986: King and Robins, 2006).  
The critical steps in metastasis are illustrated in Figure 1.3. 
 
 
Figure 1.3  The process of metastasis (Gallagher, 1985). 
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There are three modes of transporting tumour cells from a primary site to a 
secondary site: blood vessels, lymphatic vessels and movements within the body 
cavities (King and Robins, 2006). 
  
1.2  The Breast 
  The breast is a hemispherical-shaped elevation of the anterior thorax which 
houses the mammary glands, which are accessory organs of the female reproductive 
system specialized to secrete milk following pregnancy. They are located in the 
subcutaneous tissue of the anterior thorax. The breasts overlie the pectoralis major 
muscles and extend from the second to the sixth ribs and from the sternum 
(breastbone) to the axillae (underarm). A nipple is located near the tip of each breast 
and is surrounded by a circular pigmented area called the areola (Hole, 1990). 
A mammary gland is composed of 15 to 20 irregularly shaped lobes divided 
by connective and adipose (fatty) tissues. Each lobe is subdivided into lobules 
(Giometti et al., 1995). The lobules contain glandular alveoli that secrete milk 
during lactation. The alveoli secrete milk into a series of secondary tubules, which 
converge to form a series of mammary ducts. These converge to form a lactiferous 
duct that drains at the tip of the nipple. However, just beneath the nipple’s surface, 
the lumen of each lactiferous duct expands to form an ampulla, where milk 
accumulates during nursing (Fox, 1999).  
The connective tissues support the mammary glands and attach them to the 
fascia of the underlying pectoral muscles. Other connective tissue, called suspensory 
ligaments, extends inward from the skin to the fascia and helps support the breast’s 
weight. The amount of fatty tissue only determines the shape and size of a breast 
(Hole, 1990; Fox, 1999). The lactiferous ducts consist of a basal and a luminal layer. 
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The basal layer contains myoepithelial cells and a pluripotent stem cell population 
from which basal, luminal and secretory epithelial cells differentiate (Dulbecco et al., 
1986). 
 
Figure 1.4 Saggital view of the structure of the breast and mammary 
glands (Fox, 1999). 
 
1.3  Breast Cancer 
Breast cancer is a condition where malignant tumour cells form in tissues of 
the breast, usually the ducts and lobules. About 85 percent of breast cancers 
originate in the mammary ducts, while about 15 percent arise in the lobules 
(Dickson, et al., 2005). It occurs in both men and women, although it is rare in 
males (National Cancer Institute, 2008). Although these tumours maybe localized, 
they may metastasize to other parts of the body to form secondary tumours. 
The most common symptoms in breast cancer are a change of how the 
breasts or nipples feel. Most commonly, there is a lump or thickening in or near the 
breast or in the underarm area. Other symptoms are nipple changes such as 
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tenderness or discharge. In some cases, changes in the size, contour or shape of the 
breast, a nipple turned inward and changes in the skin of the breast, areola or nipple. 
In advanced stages, the tumour growth may ulcerate through the skin and become 
infected. Bone pain, liver tenderness, severe headaches, shortness of breath and a 
chronic persistent cough may be an indication that the cancer has spread (Gillett, 
1999; Malaysian Oncological Society, 2007; National Cancer Institute, 2007b; 
Oncolink, 2008). 
Early stage detection of breast cancer is often by breast self-examination. 
Commonly used screening methods for breast cancer are mammography, magnetic 
resonance imaging (MRI), ultrasound and needle biopsy (Nancer Cancer Institute, 
2005c; Harris, 2005; Malaysian Oncological Society, 2007). After a microscopic 
examination of the cancer cells, the stage and grade can be established. Common 
forms of treatment for breast cancer are conservative surgery, mastectomy, 
radiotherapy, chemotherapy, hormonal therapy and targeted therapy (Malaysian 
Oncological Society, 2007; National Cancer Institute, 2007d). More recent forms of 
advanced treatment which are less invasive include: Radiofrequency ablation, 
cryoablation, interstitial laser ablation and focused ultrasound ablation (Huston and 
Simmons, 2005). 
 
1.3.1 Major Forms of Breast Cancer 
The most common forms of breast cancer originate in the ducts or lobules 
of the breast. The cancer’s point of origin is determined by an examination of the 
cells’ microscopic appearance taken from a biopsy. In general, breast cancer can be 
categorized as in situ or non-invasive and infiltrating or invasive. 
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In in situ breast cancer, the cancer cells are confined within their point of 
origin and have not invaded the surrounding breast tissues. Two common forms of in 
situ breast cancer are ductal carcinoma in situ and lobular carcinoma in situ. 
Ductal carcinoma in situ (DCIS) is a condition where the tumour cells 
develop in the lining of the lactiferous duct but have not yet invaded the surrounding 
breast tissue. Detected early, almost all DCIS cases can be successfully treated. 
DCIS is considered an early-stage breast cancer but may progress to infiltrating 
ductal carcinoma if left untreated. DCIS accounts for 90% of all in situ breast cancer 
cases (Gillett, 1999; MayoClinic, 2007). 
Lobular carcinoma in situ (LCIS) is a tumour of the lobular cells in the 
breast which has not invaded the surrounding tissue. It does not usually progress to 
invasion but patients with LCIS are thought to be at an increased risk of developing 
invasive breast cancer at some point in their future (Gillett, 1999; MayoClinic, 
2007). 
Infiltrating or invasive breast cancers are capable of breaking free from 
their point of origin and invade the surrounding breast tissues. They also have the 
ability to travel to other parts of the body causing secondary tumours. Two major 
forms of infiltrating breast cancer are infiltrating ductal carcinoma and infiltrating 
lobular carcinoma. 
In infiltrating ductal carcinoma (IDC), tumour cells formed in the lining of 
the lactiferous duct break free of the ductal wall and invade the surrounding tissue.  
IDC is the most common form of invasive breast cancer, accounting for about 85% 
of all cases (Molland et al., 2004; Dickson, et al., 2005; American Cancer Society, 
2006a; Oncolink, 2007). The tumour cells in IDC may remain localized or they may 
metastasize to other parts of the body (MayoClinic, 2005) 
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In infiltrating lobular carcinoma (ILC), the tumour cells originate in the 
lobules of the breast and invade the surrounding tissue. As with IDC, they can 
metastasize to other parts of the body. Unlike IDC, it is harder to detect as a lump 
my not be detected and is likely to appear on a mammogram (MayoClinic, 2007). 
 
1.3.2 Less Common Forms of Breast Cancer 
Inflammatory breast cancer is a rare but aggressive type of breast cancer 
where the tumour cells block the lymph vessel near the surface of the breast 
resulting in reddening and swelling of the skin of the breast. Medullary carcinoma is 
a specific type of invasive breast cancer where the boundary between tumour and 
normal cells are clearly defined. Mucinous or colloid carcinoma is an invasive breast 
cancer where the tumour cells produce mucus and the tumour takes on a jelly-like 
appearance. Paget’s disease is a rare type of breast cancer that affects the nipple and 
the areola. Tubolar carcinoma is a rare form of breast cancer. Phylloides tumours 
develop in the connective tissue of the breast rather than the lobules or ducts. 
Metaplastic carcinoma tends to remain localized and contain several different types 
of cells that are not usually seen in other forms of breast cancer. It represents less 
than 1% of all newly diagnosed breast cancers (Oncolink, 2001; MayoClinic, 2007). 
 
1.3.3 Breast Cancer Stages 
Staging is a system of classifying patients based on the extent of the cancer 
in the primary site and how much it has spread to other parts of the body (National 
Cancer Institute, 2007e). Staging defines the extent of spread of a cancer (Jass, 
1999). This information is used to plan treatment and to find out a patient’s 
prognosis. To overcome weakness of older staging systems, the American Joint 
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Committee on Cancer (AJCC) developed the TNM classification system as a tool for 
doctors to stage different types of cancer based on certain standard criteria (Greene 
et al., 2002). 
The TNM system is based on the extent of the tumour (T), the extent of 
spread to the lymph nodes (N), and the presence of metastasis (M). A number is 
added to each letter to indicate the size or extent of the tumour and the extent of 
spread (National Cancer Institute, 2007e). 
The evaluation of cancer staging follows the T, N, M system as shown 
below: 
Primary Tumor (T)  
TX:  Primary tumour cannot be evaluated  
T0:  No evidence of primary tumour  
Tis:  Carcinoma in situ  
T1, T2, T3 or T4: Size and/or extent of the primary tumour  
 
Regional Lymph Nodes (N)  
NX:  Regional lymph nodes cannot be evaluated  
N0:  No regional lymph node involvement  
N1, N2 or N3: Involvement of regional lymph nodes  
 
Distant Metastasis (M)  
MX:  Distant metastasis cannot be evaluated  
M0:  No distant metastasis  
M1:  Distant metastasis  
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Once the T, N, and M have been established, they are combined and an 
overall breast cancer stage is assigned. 
 
Table 1.1 Breast cancer staging system (Greene et al., 2002). 
 
Stage Description 
0 Lobular or ductal carcinoma in-situ. Contained cancer which has not 
spread through the ductal system. 
I Tumour is smaller than 2cm and has not spread to any lymph nodes. 
IIa Tumour is smaller than 2cm, spread to 1-3 underarm lymph nodes. 
Tumour is between 2-5cm and has not spread to any lymph nodes. 
IIb Tumour is between 2-5cm. spread to 1-3 underarm lymph nodes. 
Tumour is larger than 5cm and has not spread to lymph nodes and 
does not grow into chest wall. 
IIIa Tumour is smaller than 5cm, spread to 4-9 underarm lymph nodes.  
Tumour is larger than 5cm and has spread to 1 to 9 axillary nodes or 
to internal mammary nodes. 
IIIb Tumour has grown into the chest wall or skin and may have spread 
to other lymph nodes or as many as 9 underarm nodes. Mammary 
nodes may or may not be involved. 
IV Tumour has spread out to other parts of the body (Metastasis). 
 
1.3.4 Breast Cancer Grades 
Grading is a way of classifying tumour cells by how abnormal they appear 
under a microscope and how quickly they are likely to spread (National Cancer 
Institute, 2004). The grading system determines the biological aggressiveness of 
cancer cells (Jass, 1999). Patients are assigned a grade to their breast cancer to 
identify the type of tumour present and help determine the patient’s prognosis. The 
AJCC has a general guideline on cancer grading classifications. The 
Scarff-Bloom-Richardson system is one the most common type of breast cancer 
grade system used. Three features are observed when determining a cancer’s grade: 
tubule formation (the percentage of cancer composed of tubular structures), nuclear 
pleomorphism (change in cell size and uniformity) and the frequency of cell mitosis 
12 
 
(rate of cell division). Each of these features is assigned a score ranging from 1 to 3 
where 1 indicates slower cell growth and 3 a faster cell growth (American Cancer 
Society, 2006b; Oncolink, 2007; Imaginis, 2008).  
 
Table 1.2 Scarff-Bloom-Richardson grading system (Oncolink, 2007; 
Imaginis, 2008). 
 
Tubule Formation Score 
More than 75% 1 
Between 10% and 75% 2 
Less than 10% 3 
Nuclear Pleomorphism Score 
Small, uniform cells 1 
Moderate increase in size and variation 2 
Marked variation 3 
Frequency of cell mitosis Score 
Up to 7 1 
Between 8 and 14 2 
15 or more 3 
 
The scores of each of the cells’ features are added together for a final sum 
ranging from 3 to 9. 
 
Table 1.3 Grading of breast cancer by score (American Cancer Society, 
2006b; Oncolink, 2007; Imaginis, 2008). 
 
Grade Description Score 
1 Well-differentiated cells; cells generally appear normal 3,4,5 
and are not growing rapidly; cancer arranged in small 
tubules. 
2 Moderately-differentiated cells; have characteristics 
between Grade 1 and Grade 3 tumours. 
6,7 
3 Poorly differentiated breast cells; cells do not appear 
normal and tend to grow and spread more aggressively. 
8,9 
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1.3.5 Risk Factors in Breast Cancer 
There is still no explanation as to the actual causes of breast cancer. 
Research has shown that certain risk factors, both inherited and environmental can 
predispose a person to develop breast cancer (National Cancer Institute, 2007a).   
Women are 100 times likely to get the disease than men (American Cancer 
Society, 2006). The chances of getting breast cancer increases with age (Pike et al., 
1983; American Cancer Society, 2006a). The risks are also affected by a women’s 
reproductive and menstrual history, especially the total accumulated exposure to 
ovarian oestrogen, early menarche and late menopause (Henderson at al., 1996; 
Kelsey and Bernstein, 1996; Colditz and Rosner, 2000). Women with a family 
history of the disease or who are carriers of the BRCA1 and BRAC2 genes have an 
increased risk (Henderson, et al., 1996; Ponder, 2003). Other risk factors include: 
Race or ethnicity (National Cancer Institute, 2007a), history of prior breast biopsy 
(Fitzgibbons, 1998). Physical exercise (Friedenreich, 2001), exposure to radiation 
(National Cancer Institute, 2007a). The risk is increased in women who consume 
alcohol at harmful levels (Ridolfo and Stevenson, 2001). The use of hormonal 
replacement therapy (HRT) after menopause appears to increase the risk of getting 
breast cancer (Colditz et al., 1995). However the issue of HRT as a risk factor is still 
under discussion (Malaysian Oncological Society, 2007). 
 
1.3.6 Epidemiology of Breast Cancer 
Breast cancer is the fifth leading form of cancer death worldwide where it 
accounted for 548,000 deaths (7% of all cancer deaths) worldwide in 2007. However, 
it is the most common form of cancer affecting women (American Cancer Society, 
14 
 
2006d; World Heath Organization, 2008). In most Western countries, it is the leading 
cause of cancer death in women between the ages 40 and 55 (Plant, 2001). 
In the United States, breast cancer is the most common form of cancer in 
women, and the second most common cause of cancer death in women after lung 
cancer. In 2007, invasive breast cancer is expected to affect 178,480 women and 
cause 40,910 deaths or 7% of all cancer deaths in the U.S. (American Cancer Society, 
2006d). Women in the U.S. and Europe have a 12.5% chance of developing invasive 
breast cancer in their lifetime and a 1 in 33 chance of breast cancer causing their 
deaths.  
In Malaysia, 3738 female breast cancer cases were reported in 2003, 
making it the most diagnosed cancer among women. It accounted for 31% of newly 
diagnosed female cases. It is the most common form of cancer in all ethnic and age 
groups in women from the age of 15. Of the reported cases in 2003, 64.1% were in 
women between ages 40 and 60 years. The overall age specific rate (ASR) was 46.2 
per 100,000 women. Of these, Chinese females had the highest ASR of 59.7 per 
100,000 women, followed by Indian females with an ASR of 55.8 per 100,000 and 
Malay females with a 33.9 per 100,000 ASR. In 2003, the age pattern shown a peak 
age specific incidence rate of between ages 50-59 in Malays, Chinese and Indian, 
although this declined in older age groups (Lim and Halimah, 2004). About one in 
19 women in Malaysia run the risk of developing breast cancer (Malaysian 
Oncological Society, 2007). 
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1.4  Proteomic Analysis and Protein Identification 
Proteomics is the large-scale study of the proteome, particularly their 
structures and functions (Liebler, 2002). The concept of proteomics and proteome 
was first proposed by Wilkins in 1995 where the proteome is used to describe the 
entire complement of proteins expressed by a genome, cell, tissue or organism. 
Proteome analysis is a measurement of proteins in terms of their presence and 
relative abundance (Wilkins et al., 1996). The ultimate aim of proteomics is to 
characterize protein pathways, networks and signaling events of cell regulation in 
diseases (Somiari et al., 2004). 
The study of proteomics can be divided into 3 main categories: Proteomic 
analysis, expression proteomics and cell-mapping proteomics. Proteomic analysis is 
the large-scale identification and characterization of proteins, including their 
post-translational modifications. Analyses are usually done using mass spectrometry. 
Expression proteomics uses proteomic tools such as two-dimensional gel 
electrophoresis and high performance liquid chromatography for global profiling of 
expressed proteins in cell lysates and tissues. As with proteomic analysis, analyses 
of protein identities are done by mass spectrometry. Cell-mapping proteomics 
utilizes the identification of protein complexes to determine protein to protein 
interactions and intracellular signaling circuitry (Simpson, 2003). 
In current practice, proteomics encompasses four main applications: 
Proteome mining, protein expression profiling, identification of protein-protein 
interactions in protein complexes, and protein modification profiling. Proteome 
mining attempts to identify as many components of the proteome as possible. 
Protein expression profiling aims to detect and measure differences in protein 
expression between samples. It is used to identify proteins that are expressed 
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normally and in the presence of a disease in a living system. In protein-protein 
interactions identification, the identity and function of the individual proteins are 
determined before working out how they interact with one another. The purpose of 
profiling protein modifications is to establish when proteins are modified after their 
synthesis (Liebler, 2002; Simpson, 2003). 
Mass spectrometry (MS) based methods (Mann and Talbo, 1996) for the 
identification of gel-separated proteins have become an essential tool in proteomics. 
It has replaced Edman’s degradation as a protein identification tool as it is more 
sensitive, has higher throughput and able to identify proteins in the presence of other 
proteins (Simpson, 2003). Current MS based methods rely on the separation of 
proteins with either one-dimensional (Laemmli, 1970) or two-dimensional 
electrophoresis (O’Farrell, 1975) followed by proteolytic digestion of the proteins 
(Schevchenko et al., 1996).  The peptide mass or the sequence information from 
fragmented peptides is usually sufficient to allow unambiguous protein identification 
(Simpson, 2003). 
 
1.4.1 Sample Preparation 
Sample preparation is one of the most critical steps in proteomics (Link, 
1999; Rabilloud, 1999; Molloy, 2000) and in producing optimal and reproducible 
results in proteomics (Dunbar, 1987). It is perhaps the most important step in 
proteome analysis as this step will influence protein yield (Simpson, 2003; Dhingra 
et al., 2005). An effective sample preparation will yield a high concentration of 
proteins as well as free of salts and other interfering substances such as nucleic acids 
and lipids which can interfere with subsequent protein analysis (Jiang et al., 2004). 
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Ideally, the process will result in the complete solubilization of proteins in the 
extraction buffer (Rabilloud, 1996).  
Sample preparation usually starts with tissue lysis or disruption, which 
should be done in a solubililizing solution. The sample can be precipitated to remove 
interfering substances before being resolubilized in the solubilizing solution. In 
general, it is best to keep sample preparation as simple as possible (Simpson, 2003). 
 
1.4.2 Tissue Disruption and Sequential Extraction 
The first step of a sample preparation protocol is to wash the tissue, disrupt 
the tissue in a suitable buffer using homogenizer. The homogenate is centrifuged to 
separate the pellet from the supernatant. There are many methods to homogenize 
tissues but the ultimate purpose is to break the tissue or cell in order to release 
proteins (Görg et al., 2000). The centrifugation process will separate soluble 
proteins in the supernatant from the insoluble proteins and cell debris that remain as 
pellet. A stronger solubilizing solution is then added to solubilize the remaining 
proteins in the pellet. This method is known as sequential extraction where proteins 
are sequentially extracted in increasingly powerful solubilizing solutions (Molloy et 
al., 1998; Simpson, 2003).  
 
1.4.3 Precipitation  
Samples usually contain contaminating substances such as salts, detergents, 
nucleic acids and lipids. These contaminants can interfere with subsequent 
proteomic analysis such as two-dimensional polyacrylamide gel electrophoresis 
(2D-PAGE). Samples are precipitated and centrifuged. The contaminants remain 
soluble in the supernatant will be removed by discarding the supernatant. The 
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protein pellet is resuspended in a solubilizing solution. This has an added advantage 
of concentrating the protein (Simpson, 2003) and inactivating proteases (Rabilloud 
and Chevallet, 2000). One of the methods used to precipitate proteins is by 
trichloroacetic acid/acetone (TCA/A) precipitation that is known for its high protein 
recovery and ease of use (Görg et al., 1988a, 1997; Tsugita and Kamo, 1999; Jiang 
et al., 2004). 
 
1.4.4 Sobulization 
Solubilizing solutions are a mixture of chemicals to fully solubilize proteins. 
These chemicals must not interfere with 2D-PAGE and also keep the proteins in 
their solubilized state during 2D-PAGE runs. In sequential extractions, the first 
solubilizing solution is Tris while the subsequent solution is thiourea lysis buffer 
(TLB), which has a comparatively higher solubilizing properties. TLB contains 
chemicals such as chaotropic agents, detergents, reducing agents and ampholytes 
(Molloy et al., 1998). 
Tris [tris(hydroxymethyl)aminomethane] is widely used in biochemistry 
and molecular biology as a buffer (Gomori, 1955). A buffer is a substance where its 
presence resists changes in pH by increasing the amount of acid or alkali required 
for the change (van Slyke, 1922; Campbell and Farrell, 2006). Tris is slightly basic 
with a pKa of 8.08 (Bates and Pinching, 1949) which makes it suitable for studies in 
biological systems as well as pH control in vitro (Nahas, 1961; Bates et al., 1978). It 
is used at a concentration of 40mM to solubilize aqueous soluble proteins (Molloy et 
al., 1998; Santoni et al., 2000). 
Chaotropic agents denature proteins by disrupting their hydrogen bonds. 
The disruption prevents unwanted protein aggregation or formation of secondary 
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structures that affect protein mobility. Urea is one of the most widely used 
chaotropic agents. It maintains proteins in their denatured state, keeps them soluble 
and unfolds most proteins to their fully random conformation (Dunbar, 1987). Urea 
is typically used at a concentration of 8M. However, as some proteins still do not get 
denatured at high urea concentrations (Tanford, 1968), the addition of thiourea can 
improve the solubility of proteins, particularly membrane proteins (Pasquali et al., 
1997; Rabilloud et al., 1997; Rabilloud, 1998).  
Detergents ensure complete sample solubilization and prevent protein 
aggregation by disrupting protein hydrophobic interactions. They also increase 
protein solubility at their respective isoelectric point (pI). For proteins to be 
separated by 2D-PAGE, the detergents used must be non-ionic or zwitterionic to 
allow proteins to migrate according to their own charges (Berkelman and Stenstedt, 
1998). The use of detergents is quite important as some proteins, especially 
membrane proteins require the presence of detergents to sustain their solubility 
during isolectric focusing (IEF) (Garfin and Heerdt, 2000). 
Earlier use of non-ionic detergents in 2D-PAGE (Klose, 1975; O’Farrell, 
1975) has been superseded by the use of zwitterionic cholamidosulfobetaine 
detergents 3-[3-cholamidopropyl]dimethylammonio]-1-propane sulfonate (CHAPS) 
and its hydroxyl analog 
3-[3-cholamidopropyl]dimethylammonio]-2-hydroxy-1-propane sulfonate 
(CHAPSO) (Perdew et al., 1983). CHAPS is a non-denaturing detergent for 
solubilizing proteins and is available in high purity and can be used at 
concentrations up to 4% in isoelectric focusing (IEF) (Garfin, 1990; Herbert, 1999; 
Simpson, 2003). It is especially suitable for protein solubilization in 2D-GE 
(Hjelmel and Chrambach, 1981; Garfin, 1990; Schupbach et al., 1991). Other 
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detergents such as SB-10 are also used (Adessi et al., 1997; Molloy et al., 1998) but 
they are relatively insoluble in the presence of urea. A typical concentration of 
detergents in solubilization buffers is commonly in the range of 0.5-4%.  
During IEF, some proteins tend to precipitate at their pI even in the 
presence of chaotropic agents and detergents. Therefore, carrier ampholytes are 
added to improve protein solubility by maintaining the optimum pH for maximum 
protein solubility and by minimizing protein aggregation due to charge-charge 
interactions (Garfin and Heerdt, 2000; Simpson, 2003). Carrier ampholytes also 
ensure uniform conductivity during IEF without altering the pH gradient of the IPG 
strip. The concentration of carrier ampholytes in sample preparation is typically 
0.2-0.4% (w/v). 
Reducing agents are used in solubilization buffers to cleave disulfide bonds 
between cysteine residues and to maintain proteins at their reduced state (Liu, 1977). 
This allows proteins to be analyzed as single subunits (Garfin and Heerdt, 2000). 
Originally, 2-mercaptoethanol was used to reduce samples for 2D-GE, but because it 
has some disadvantages (Marshall and Williams, 1984), it has been superseded by 
the sulfhydril reducing agent 1,4 – dithiothreitol (DTT) (Cleland, 1964). The 
concentration of DTT used is between 20 to 100mM but 50mM is usually effective 
in breaking disulfide bonds (Garfin and Heerdt, 2000). 
Homogenization of tissue samples not only releases proteins but also 
proteases. These proteases can degrade proteins and complicate analysis of 
2D-PAGE results (Berkelman and Stenstedt, 1998; Simpson, 2003). Protease 
inhibitors inhibit the activity of proteases. Phenyl methyl sulphonyl fluoride (PMSF) 
and AEBSF [4-(2-aminoethyl) benzylsulfonyl fluoride] are examples of inhibitors of 
serine and cysteine proteases (Mintz, 1993; Simpson, 2003). They inhibit the 
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proteases’ function by forming covalent bonds with these proteases. Typical 
concentrations used are between 1 to 10mM. 
 
1.4.5 Electrophoresis 
Electrophoresis refers to the transport of charged particles or molecules 
through a solvent or matrix in an electric field towards their opposing charges 
(Dunbar, 1987; Campbell and Farrell, 2006). The separation of molecules not only 
depends on the size, shape and net charge of the molecule, but also by voltage, 
electrode distance, medium viscosity, temperature and time (Simpson, 2003). Since 
different proteins have different shapes and net charges, each protein will migrate in 
an electrophoretic field at a different rate (Dunbar, 1987). In general, proteins with a 
positive and negative net charge migrate to the cathode and anode electrodes 
respectively, while neutral charged proteins do not move at all (McKee and McKee, 
1999). 
The use of electrophoresis to resolve proteins is widely used in 
biochemistry and proteomics due to its resolving power, versatility and adaptability 
(Figeys et al., 1998). Not only does it separate proteins, it allows crucial protein 
properties such as isoelectric point (pI) and molecular weight (MW) to be 
determined (Nelson and Cox, 2006). Most electrophoretic procedures today are 
based on zone electrophoresis (Hames, 1990) or discontinuous electrophoresis 
(Davis, 1964; Ornstein, 1964) in polyacrylamide gels (Raymond and Weintraub, 
1959). 
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1.4.6 Polyacrylamide Gel Electrophoresis 
Polyacrylamide is one of the most widely used matrices for carrying out 
protein seperation by electrophoresis (Dunbar, 1987). The small pore sizes of its 
matrix give polyacrylamide gels molecular sieving properties. This allows 
polyacrylamide to separate proteins based on their shape and size in addition to 
charge density (Hames, 1990). Polyacrylamide gel electrophoresis (PAGE) is one of 
the main methods used to separate proteins in complex mixtures and determining 
protein purity. It can also be used to find out a protein’s relative molecular mass, 
verify its concentration and detect protein modifications (Simpson, 2003). 
A polyacrylamide gel is formed by the free-radical vinyl polymerization of 
the monomer acrylamide into long chain polymers and cross-linking these by 
bifunctional compounds such as N,N’-methylene bisacrylamide (bisacrylamide) that 
react with free functional groups at the ends of the chain (Richards and Lecanidou, 
1974). The polymerization of acrylamide is initiated by a chemical peroxide, usually 
ammonium persulfate (APS). APS dissolved in water forms persulfate radicals that 
acts as an electron carrier that provides unpaired electrons and converts the 
acrylamide monomer to a free radical state. The free radical acrylamide monomer 
then reacts with other acrylamide monomers to begin the chain elongation and 
acrylamide polymerization (Shi and Jackowski, 1998). Tertiary or quaternary amines 
such as N,N,N’,N’-tetramethylenediamine (TEMED) are added to accelerate the 
formation of free radicals, which in turn accelerates the polymerization process The 
elongating chains are crosslinked with bisacrylamide to form a matrix with pore 
sizes depending on the acrylamide monomer concentration (Hames, 1990; Dunbar, 
1987; Simpson, 2003). The crosslink adds rigidity and tensile strength to the gel 
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(Sambrook and Russell, 2001). Bisacrylamide is an important component as without 
it the acrylamide polymer chains will not gel (Cooper, 1977). 
The composition of a polyacrylamide gel is described by the monomer 
concentration, %T and crosslinker concentration, %C (Hjertén, 1962). Generally, the 
pore size of polyacrylamide gels is inversely proportional to %T (Hames, 1990). 
Polyacrylamide gels are the separation media in isoelectric focusing (IEF) 
and sodium dodecyl sulfate polyacrlyamide gel electrophoresis (SDS-PAGE). IEF 
and SDS-PAGE are components of two-dimensional gel electrophoresis (2D-GE), 
where proteins are separated by two different parameters, i.e. pI and MW. 2D-PAGE 
is one of the most effective and powerful means of resolving and analyzing complex 
mixtures. (Celis and Bravo, 1984; Dunbar, 1987; Liebler, 2002; Simpson, 2003). 
 
1.4.7 Isoelectric Focusing 
Proteins are amphoteric molecules that carry either a positive, negative or 
zero net charge depending on the pH of their surroundings (Simpson, 2003). The net 
charge of a protein molecule depends on the sum of all charges of its amino acid side 
chains (Dunbar, 1987). At a specific pH, the net charge of a protein will be zero, and 
this pH value is referred to as the protein’s pI. 
Isoelectric focusing (IEF) is a form of electrophoresis where proteins are 
separated based on their pI. A protein is placed in a medium with a pH gradient and 
is subjected to an electric field at the same time. In the presence of a pH gradient, a 
protein will migrate to the position in the gradient equal to its pI. A protein that 
migrates nearer to its pI becomes less charged until it stops at its pI as it has no net 
charge. This is the focusing effect of IEF, which concentrates proteins at their pI and 
allows separation of proteins on the basis of very small differences in net charge 
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